A two-year grant fueling breakthroughs in leukemia and MDS by emerging independent researchers. Provides seed funding to new investigators worldwide to launch innovative leukemia research projects. Aims to bridge the gap for early-career faculty pursuing novel ideas in leukemia biology or treatment.
Eligibility Criteria:
- Early-career independent investigators (within 7 years of first faculty appointment) at non-profit institutions. Must be in a tenure-track or equivalent role with own lab space.
- Global eligibility: Open to applicants from any country; U.S. citizenship not required. (Researchers outside the Americas are eligible, as well as those in North/South America.)
- Must not hold major grants ≥ $175k/year or an active NIH R01 at time of application. KO8, K99/R00 awards are permitted.
Funding Details:
- Amount/Duration: Up to $150,000 USD total, disbursed over 2 years (max $75k/year).
- Purpose: Supports hypothesis-driven basic or translational research with potential to impact leukemia or myelodysplastic syndromes (MDS) outcomes. Can cover personnel, supplies, and small equipment (≤ $7.5k).
- Grant term starts July 1, 2026 (for the 2026–2028 cycle).
Deadline:
- February 6, 2026 – Letter of Intent (LOI) due (by 12:00 Noon U.S. CT). Invited full applications will be due April 13, 2026, with award notifications by June 2026.
Where to go for further information: